Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Science Officer | February 27, 2024 | February 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date February 27, 2024 · Filed February 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 69,771 |
Reported balance
After 2024-02-27 transaction · row 1
1 source rowRow 1 · 2024-02-27 · Grant · Acquired 51,124 · Balance 69,771 F1: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.30 · Expires 2034-02-26 | Direct | 78,174 |
Reported balance
After 2024-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-27 · Grant · Acquired 78,174 · Balance 78,174 F2: Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F2: Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2024 Filed Feb 29, 2024 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 78,174 | $16.30 Strike: $16.30 | $1,274,236.20 |
DisclosureSEC source: 0001562180-24-001984 · primarydocument.xml · derivative · entry 2 Giladi Moshe · CIK 0002001639 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,174 Underlying: Ordinary Shares · 78,174 shares Expires 2034-02-26 F2 · derivative.exercise_date: Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 51,124 | $16.30 | $833,321.20 |
DisclosureSEC source: 0001562180-24-001984 · primarydocument.xml · nonDerivative · entry 1 Giladi Moshe · CIK 0002001639 · Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,771 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.